BR112014006535A2 - regulação dos canais de sódio através das proteínas plunc - Google Patents

regulação dos canais de sódio através das proteínas plunc

Info

Publication number
BR112014006535A2
BR112014006535A2 BR112014006535A BR112014006535A BR112014006535A2 BR 112014006535 A2 BR112014006535 A2 BR 112014006535A2 BR 112014006535 A BR112014006535 A BR 112014006535A BR 112014006535 A BR112014006535 A BR 112014006535A BR 112014006535 A2 BR112014006535 A2 BR 112014006535A2
Authority
BR
Brazil
Prior art keywords
sodium channels
sodium
plunc
regulation
proteins
Prior art date
Application number
BR112014006535A
Other languages
English (en)
Inventor
Jack Stutts Monroe
Tarran Robert
Donaldson Scott
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of BR112014006535A2 publication Critical patent/BR112014006535A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

regulation of sodium channels by plunc proteins abstract the present invention relates to the ability of plunc proteins, such as splunc1 and splunc2, to bind to sodium channels and inhibit activation of the sodium channels. the invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of plunc proteins to sodium channels. 78 ********************************************************* tradução do resumo resumo patente de invenção: "regulação dos canais de sódio através das proteínas plunc". a presente invenção refere-se à capacidade das proteínas plunc, tais como splunc1 e splunc2, em se ligar aos canais de sódio e inibir a ativação dos canais de sódio. a invenção refere-se ainda aos métodos para a regulação da absorção de sódio e do volume de fluido e tratamento dos distúrbios sensíveis à modulação da absorção de sódio mediante a modulação da ligação de proteínas plunc aos canais de sódio.
BR112014006535A 2011-09-20 2012-09-19 regulação dos canais de sódio através das proteínas plunc BR112014006535A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536647P 2011-09-20 2011-09-20
PCT/US2012/056112 WO2013043720A1 (en) 2011-09-20 2012-09-19 Regulation of sodium channels by plunc proteins

Publications (1)

Publication Number Publication Date
BR112014006535A2 true BR112014006535A2 (pt) 2017-03-28

Family

ID=47914825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006535A BR112014006535A2 (pt) 2011-09-20 2012-09-19 regulação dos canais de sódio através das proteínas plunc

Country Status (13)

Country Link
US (2) US9127040B2 (pt)
EP (1) EP2760463B1 (pt)
AU (2) AU2012312520A1 (pt)
BR (1) BR112014006535A2 (pt)
CA (1) CA2849267A1 (pt)
DK (1) DK2760463T3 (pt)
ES (1) ES2716723T3 (pt)
HK (1) HK1200729A1 (pt)
HU (1) HUE041740T2 (pt)
IL (1) IL231614B (pt)
PL (1) PL2760463T3 (pt)
PT (1) PT2760463T (pt)
WO (1) WO2013043720A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138794A2 (en) 2009-05-29 2010-12-02 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
RU2017115994A (ru) 2014-10-08 2018-11-12 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Улучшенные пептидные ингибиторы натриевых каналов
CA2988046A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
AU2016333907A1 (en) 2015-10-09 2018-04-12 AbbVie S.à.r.l. Novel compounds for treatment of cystic fibrosis
ES2829636T3 (es) 2015-10-09 2021-06-01 Abbvie Overseas Sarl Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso
TW201735769A (zh) 2015-10-09 2017-10-16 盧森堡商艾伯維公司 經取代之吡唑并［３，４－ｂ］吡啶－６－羧酸及使用方法
US10894811B2 (en) 2016-02-22 2021-01-19 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
WO2018064499A1 (en) * 2016-09-29 2018-04-05 Spyryx Biosciences, Inc. Peptide inhibitors of sodium channels
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
CA3046361A1 (en) * 2016-12-13 2018-06-21 Spyryx Biosciences, Inc. Saline formulations of splunc1 peptides
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
CN106749679A (zh) * 2017-01-10 2017-05-31 中国人民解放军疾病预防控制所 抗P选择素单链抗体靶向抑制物融合蛋白ScFv‑SPLUNC1及其表达方法与应用
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
CA3157798A1 (en) 2019-11-12 2021-05-20 Zhongli Gao 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022204185A1 (en) * 2021-03-22 2022-09-29 The University Of North Carolina At Chapel Hill Modified peptidomimetics and methods of use
WO2023034992A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof
WO2024054840A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions, and methods of using thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
JP2001510457A (ja) 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US7384910B2 (en) * 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
WO2005056045A1 (en) * 2003-12-04 2005-06-23 The University Of Iowa Research Foundation Methods and compositions related to plunc polypeptides
US20070161018A1 (en) 2005-11-04 2007-07-12 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
WO2010138794A2 (en) 2009-05-29 2010-12-02 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins

Also Published As

Publication number Publication date
PT2760463T (pt) 2019-02-27
AU2018200871A1 (en) 2018-02-22
WO2013043720A1 (en) 2013-03-28
EP2760463A1 (en) 2014-08-06
PL2760463T3 (pl) 2019-05-31
EP2760463B1 (en) 2018-11-21
HUE041740T2 (hu) 2019-05-28
DK2760463T3 (en) 2019-03-18
ES2716723T3 (es) 2019-06-14
US20140228276A1 (en) 2014-08-14
US9127040B2 (en) 2015-09-08
EP2760463A4 (en) 2015-07-29
IL231614B (en) 2019-02-28
IL231614A0 (en) 2014-05-28
HK1200729A1 (en) 2015-08-14
US20160159879A1 (en) 2016-06-09
CA2849267A1 (en) 2013-03-28
AU2012312520A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
BR112014006535A2 (pt) regulação dos canais de sódio através das proteínas plunc
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BR112014028991A2 (pt) triazóis como inibidores de kv3
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591367A1 (ru) Соединения резорцина для дерматологического применения
BR112015021618A2 (pt) métodos e composições para controle de ervas daninhas
BR112012029904A2 (pt) métodos de purificação de polipeptídeos
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
EA201170349A1 (ru) Модуляторы mif
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
MX2015010749A (es) Anticuerpos humanos para nav1.7.
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
BR112015026258A2 (pt) composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201590136A1 (ru) Искусственные консенсусные альбумин-связывающие домены

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]